Pulmatrix Inc

NASDAQ PULM

Data sourced from iex and EODHD
Download Data

Pulmatrix Inc Price to Earnings Ratio (P/E) on June 03, 2024: -1.88

Pulmatrix Inc Price to Earnings Ratio (P/E) is -1.88 on June 03, 2024, a -226.76% change year over year. The price to earnings ratio (P/E ratio) compares the market price per share of a company's stock to its earnings per share (EPS). It is calculated by dividing the market capitalization by the net income, divided by the number of outstanding shares. This ratio provides insights into the market's valuation of a company's earnings. A higher P/E ratio indicates that investors are willing to pay a higher price for each unit of earnings, suggesting higher market expectations for future earnings growth.
  • Pulmatrix Inc 52-week high Price to Earnings Ratio (P/E) is -0.43 on September 27, 2023, which is 76.84% above the current Price to Earnings Ratio (P/E).
  • Pulmatrix Inc 52-week low Price to Earnings Ratio (P/E) is -583.50 on August 08, 2023, which is -31,004.90% below the current Price to Earnings Ratio (P/E).
  • Pulmatrix Inc average Price to Earnings Ratio (P/E) for the last 52 weeks is -7.61.
NASDAQ: PULM

Pulmatrix Inc

CEO Mr. Teofilo David Raad MBA
IPO Date March 21, 2014
Location United States
Headquarters 99 Hayden Avenue, Lexington, MA, United States, 02421
Employees 22
Sector Healthcare
Industry Biotechnology
Description

Pulmatrix, Inc., a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clinical trials for the treatment of acute exacerbations in chronic obstructive pulmonary disease; PUR1900 for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis; and PUR3100, an iSPERSE formulation of dihydroergotamine which is in Phase 1 for the treatment of acute migraine. It has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates. The company was founded in 2003 and is headquartered in Bedford, Massachusetts.

StockViz Staff

September 20, 2024

Any question? Send us an email